DEF: BlueRiver Acquisition Corp. Seeks Shareholder Approval to Extend Business Combination Deadline Amidst OTC Market Transition

BlueRiver Acquisition Corp. is seeking shareholder approval to extend its deadline for completing an initial business combination by up to 12 months, from August 2, 2025, to August 2, 2026, to allow more time for a suitable acquisition.

Summary

• BlueRiver Acquisition Corp. (BlueRiver), a Special Purpose Acquisition Company (SPAC), is holding an Extraordinary General Meeting on July 21, 2025, to vote on two key proposals: an Extension Proposal and an Adjournment Proposal.
• The Extension Proposal seeks to amend the company's charter to allow the Board of Directors to extend the deadline for consummating an initial business combination from August 2, 2025, to August 2, 2026, through up to four additional 3-month extensions.
• The Adjournment Proposal would allow the General Meeting to be adjourned to a later date if insufficient votes are received to approve the Extension Proposal.
• BlueRiver has not yet entered into any letter of intent or agreement for an initial business combination.
• Upon its IPO closing, $287.5 million was placed in a Trust Account. On March 28, 2023, these assets were converted to cash, and on May 4, 2023, they were deposited into an interest-bearing demand deposit account, currently yielding 3.60% per annum (variable rate).
• As of the Record Date (June 27, 2025), there were 8,079,263 outstanding ordinary shares. The per-share pro rata portion of the Trust Account, after accounting for taxes, was approximately $11.59.
• The company's units, Class A ordinary shares, and Public Warrants were delisted from NYSE American on July 15, 2024, and now trade on the OTC Expert Market under symbols BLUVF, BLUAF, and BLUAW, respectively, on an unsolicited only basis.
• Shareholders have redemption rights, allowing them to redeem their Public Shares for a pro rata portion of the Trust Account funds if the Extension Proposal is approved.

Sentiment

Score: 3

Explanation: The sentiment is largely negative due to the company's failure to secure a business combination within its initial timeframe, necessitating an extension. The delisting from NYSE American to the OTC Expert Market is a significant adverse event, severely impacting liquidity and market access for shareholders. While the company is taking steps to continue its search, these are reactive measures to challenging circumstances, and the interests of insiders may not fully align with public shareholders.

Positives

• The company's Board of Directors unanimously recommends voting for the Extension Proposal, indicating their belief in the potential for a successful business combination.
• Shareholders who do not redeem their shares will retain their redemption rights and the ability to vote on a future business combination.
• The Trust Account assets are currently held in an interest-bearing account, generating 3.60% interest per annum, which benefits remaining shareholders.

Negatives

• BlueRiver has not yet identified or entered into any agreement for an initial business combination, necessitating the extension.
• The company's securities were delisted from NYSE American and now trade on the OTC Expert Market, significantly reducing liquidity and market visibility.
• The current trading price of Ordinary Shares on the OTC Markets ($10.11 on May 29, 2025) is lower than the per-share redemption price of approximately $11.59, indicating a potential loss for shareholders selling on the open market rather than redeeming.
• The potential for significant redemptions could reduce the amount remaining in the Trust Account, potentially impacting the company's ability to complete a business combination on commercially acceptable terms.

Risks

• There is no assurance that the proposed extension will enable the company to complete a business combination.
• If the Extension Proposal is not approved, the company will automatically wind up, liquidate, and dissolve by August 2, 2025, leading to the expiration of Private Warrants and their worthlessness.
• Upon liquidation, shareholders could potentially be liable for creditor claims to the extent of distributions received if the company enters an insolvent liquidation, as there is no guarantee vendors will waive claims against the Trust Account.
• The delisting of securities from NYSE American to the OTC Expert Market has resulted in less liquidity, more limited market quotations, reduced research coverage, and increased difficulty/expense for future financings.
• An active trading market for the company's securities may never develop or be sustained on the OTC Markets, making it difficult for shareholders to sell their shares.
• The company's officers, directors, and sponsor hold a significant percentage (approximately 98.86%) of outstanding ordinary shares, and their interests in the extension (to prevent their shares and warrants from becoming worthless) may differ from public shareholders.

Future Outlook

If the Extension Proposal is approved, the company plans to continue actively searching for and attempting to consummate an initial business combination until the extended deadline of August 2, 2026. A separate shareholder meeting will be held prior to the extended date to seek approval for any proposed merger and related proposals.

Management Comments

• The Board has determined that it is in the best interests of the company's shareholders to extend the date by which the company has to complete an initial Business Combination.
• The Board unanimously recommends that you vote FOR the Extension Proposal and FOR the Adjournment Proposal.
• The Board expresses no opinion as to whether you should redeem your Public Shares.

Industry Context

This announcement reflects a common challenge faced by Special Purpose Acquisition Companies (SPACs) in identifying and completing a suitable business combination within their initial timeframe. The conversion of Trust Account assets from U.S. government securities to cash in an interest-bearing account addresses uncertainties under the Investment Company Act of 1940 for SPACs that do not consummate a business combination within 24 months of their IPO. The delisting to OTC Markets is also a trend seen with SPACs that face challenges in meeting exchange listing requirements or completing a de-SPAC transaction.

Corporate Governance

Legal Proceedings

• The document discusses the potential for creditor claims against the company upon liquidation, noting that creditors take priority over public shareholders. There is no guarantee that vendors and service providers will execute agreements waiving their rights to monies held in the Trust Account, or that such waivers would be legally enforceable.

Related Party Transactions

• BlueRiver Ventures, LLC (the Sponsor) and the company's executive officers and directors beneficially own 7,187,500 Class B Ordinary Shares and 800,000 Private Class A Shares, representing approximately 98.86% of the company's outstanding ordinary shares.
• The Sponsor, executive officers, and directors have agreed to waive their redemption rights with respect to their shares and private warrants, which would become worthless if a business combination is not completed and the company liquidates.
• The Sponsor, executive officers, and directors have agreed to vote their shares in favor of the Extension Proposal and any initial business combination.

Stakeholder Impact

• Shareholders: Face a decision to redeem their shares at a premium to the current market price or hold them in anticipation of a future business combination, with the risk of continued illiquidity on the OTC Expert Market. They retain redemption rights for a future business combination vote.
• Sponsor and Insiders: Their significant equity holdings (7,187,500 Class B Ordinary Shares and 800,000 Private Class A Shares, plus Private Warrants) are at risk of becoming worthless if the extension is not approved and no business combination is completed. They have a strong incentive to see the extension approved.
• Creditors/Vendors: Their claims would take priority over shareholders in the event of liquidation, but the company cannot assure that all will waive claims against the Trust Account, potentially leading to legal disputes.

Next Steps

• Shareholders will vote on the Extension Proposal and Adjournment Proposal at the Extraordinary General Meeting on July 21, 2025.
• If the Extension Proposal is approved, the company will continue to seek an initial business combination until August 2, 2026.
• If the Extension Proposal is approved, the company plans to hold another shareholder meeting prior to the extended date to seek approval for any proposed merger and related proposals.
• If the Extension Proposal is not approved, the company expects to take all necessary actions and hold additional general meetings until August 2, 2025, to obtain approval; otherwise, it will proceed with automatic winding up, liquidation, and dissolution.
• The company plans to apply to list its units, Class A ordinary shares, and Public Warrants on one of the public OTC Markets.

Key Dates

Recommendation

Keywords

SPAC, Special Purpose Acquisition Company, BlueRiver Acquisition Corp, Business Combination, Extension Proposal, Proxy Statement, SEC Filing, Trust Account, Redemption Rights, OTC Markets, Delisting, Corporate Governance, Liquidation